Pharmafile Logo

News and Press Releases

Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials

This investment will improve the healthcare experience for patients, reinforcing Dassault Systèmes’ role in the industry’s transformation Click Therapeutics will gain access to Dassault Systèmes’ global presence and expertise to...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 19, 2025

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

19 March 2025 -- Hong Kong, Shanghai & New Jersey, US -- HUTCHMED (China) Limited and Innovent Biologics, Inc, today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

SolasCure enrols first patient in a next Phase II clinical trial to advance Aurase Wound Gel

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers 17 March 2025 -- Cambridge,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: March 17, 2025

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

Advarra Unveils Oncology Research Pulse

Content-driven program brings together clinical trial stakeholders to foster knowledge sharing and collaboration in cancer research 12 March 2025 -- Maryland, US -- Advarra, the market leader in regulatory review...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 12, 2025

Advarra
6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

Combination of complete skin clearance data and favourable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (Pso) treated with...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

10 March 2025 -- London, UK and New York, US -- OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Innovaderm Research Rebrands as Indero, a dual-focus CRO 

7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Indero
3530 Saint-Laurent boulevard, Suite 300 Montreal, QC, H2X 2V1, Canada

Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union

4 March 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, announced that its eConsent and eCOA solutions have been approved for use in two...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections

Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Centauri
info@centauritherapeutics.com
Discovery Park, Sandwich CT13 9ND

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

4 March 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Tiziana Life Sciences
info@tizianalifesciences.com
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom

Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials

4 March 2025 -- Pennsylvania, US and Dublin, Ireland -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc, a global healthcare intelligence and clinical research...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

ICON
South County Business Park, Leopardstown, Dublin 18, Ireland

Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies

Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritis Pivotal clinical trial in osteoarthritis patients on track to start in 2025. 4 March 2025 -- Liege, Belgium -- Allegro...

Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: March 4, 2025

Allegro Bio
info@allegro.bio
Boulevard Patience et Beaujonc 3 4000 Liège Belgium

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

25 February 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025

Tiziana Life Sciences
info@tizianalifesciences.com
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom

The Bloc Launches In.Pazienti Global Community at the 7th Patient Centricity & Collaboration World Congress

25 February 2025 -- London, UK -- Today, at the 7th Patient Centricity & Collaboration World Congress in London, The Bloc unveiled In.Pazienti, a global community that connects, supports, and...

Category: Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025

The Bloc
msilver@thebloc.com
32 Old Slip, Floor 15 New York, NY 10005

ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy

Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX...

Category: Biotechnology, Clinical Trials, Other
Posted: February 25, 2025

ONWARD Medical
investors@onwd.com
Schimmelt 2. 5656 AE, Eindhoven, the Netherlands